Steven Cohen Clovis Oncology, Inc. Transaction History

Point72 Asset Management, L.P.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	SELL	$4.81 - $10.34 $8.67 Million - $18.6 Million	-1,802,756 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$4.13 - $6.41 $7.45 Million - $11.6 Million	1,802,756 New	1,802,756 $8.65 Million
Q2 2020 Aug 14, 2020	SELL	$5.69 - $9.69 $266,292 - $453,492	-46,800 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$3.77 - $11.0 $176,436 - $514,800	46,800 New	46,800 $298,000
Q2 2019 Aug 14, 2019	SELL	$12.81 - $25.67 $7.52 Million - $15.1 Million	-587,318 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$17.66 - $30.28 $8.13 Million - $13.9 Million	460,518 Added 363.18%	587,318 $14.6 Million
Q4 2018 Feb 14, 2019	SELL	$11.63 - $32.67 $25,586 - $71,874	-2,200 Reduced 1.71%	126,800 $2.28 Million
Q3 2018 Nov 14, 2018	SELL	$29.37 - $49.48 $1.06 Million - $1.78 Million	-36,000 Reduced 21.82%	129,000 $3.79 Million
Q2 2018 Aug 14, 2018	SELL	$42.06 - $62.4 $41.7 Million - $61.8 Million	-990,937 Reduced 85.73%	165,000 $7.5 Million
Q1 2018 May 15, 2018	BUY	$50.12 - $67.72 $14 Million - $19 Million	279,937 Added 31.96%	1,155,937 $61 Million
Q4 2017 Feb 14, 2018	BUY	$57.69 - $84.58 $50.5 Million - $74.1 Million	876,000	876,000 $59.6 Million

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.